Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-04-18, Stock:LLY, The news for the past five days is as follows:
2018-04-11: NEWS1: Novartis’s Valuation and Analysts’ Recommendations on April 11.NEWS2: Incyte Expected to Report Robust Revenue Growth in Fiscal 2018.NEWS3: Is Beaten-Down Incyte Corporation Stock a Buy Now?.NEWS4: Is Beaten-Down Incyte Corporation Stock a Buy Now?.NEWS5: Is Beaten-Down Incyte Corporation Stock a Buy Now?.NEWS6: A Look at Eli Lilly’s 1Q18 Stock Performance.
2018-04-12: NEWS1: Pfizer's Deal Potential Doesn't Stop at Bristol-Myers.NEWS2: Olumiant Could Boost Incyte’s Revenues.NEWS3: See what the IHS Markit Score report has to say about Eli Lilly And Co..NEWS4: Incyte Has Diversified Its Revenues across Multiple Product Lines.
2018-04-13: NEWS1: BMO's Bearish Stance On Eli Lilly Comes To An End.NEWS2: Better Buy: AbbVie Inc. vs. Eli Lilly.NEWS3: Better Buy: AbbVie Inc. vs. Eli Lilly.NEWS4: Eli Lilly's stock rallies after BMO raises rating, price target.NEWS5: Better Buy: AbbVie Inc. vs. Eli Lilly.
2018-04-16: NEWS1: Merck's Keytruda Reduces Death Risk in Melanoma Patients.NEWS2: Merck's Keytruda Reduces Death Risk in Melanoma Patients.NEWS3: VYM, QCOM, CAT, LLY: Large Outflows Detected at ETF.NEWS4: VYM, QCOM, CAT, LLY: Large Outflows Detected at ETF.NEWS5: Benzinga's Bulls & Bears Of The Week: Caterpillar, Facebook, Starbucks, Tesla And More.NEWS6: Merck&apos;s Keytruda Reduces Death Risk in Melanoma Patients.NEWS7: Boehringer Ingelheim and Lilly announce an academic collaboration with University of Oxford to investigate the effects of Jardiance® in adults with chronic kidney disease.
2018-04-17: NEWS1: Merck's Keytruda Betters Survival in Lung Cancer Combo Study.NEWS2: Merck's Keytruda Betters Survival in Lung Cancer Combo Study.NEWS3: Novartis’s Innovative Medicines Segment in 1Q18.NEWS4: Celldex's Phase II Breast Cancer Study Fails, Shares Plunge.NEWS5: Celldex's Phase II Breast Cancer Study Fails, Shares Plunge.NEWS6: 5 Drug Stocks Poised to Surpass on Earnings This Quarter.NEWS7: Celldex&apos;s Phase II Breast Cancer Study Fails, Shares Plunge.NEWS8: Expectations from Novartis’s 1Q18 Earnings.NEWS9: Risankizumab Could Be AbbVie’s Long-Term Growth Driver.

Answer: Decrease